Extracorporeal membrane oxygenation in children. New trends.
At the Children's Hospital of Pittsburgh the extracorporeal membrane oxygenation program was started in 1980. The results of our experience from 1980 to 1985 were previously reported. In the past 2 years 39 additional newborn infants have been treated with this modality, with an overall survival rate of 79% (31/39). This survival rate is much better than that obtained in 33 neonates who had been treated in the previous 5 years (54%; p less than 0.05). A new aspect of our extracorporeal membrane oxygenation program is the use of total apneic lung rest for persisting pulmonary interstitial emphysema during support with the oxygenator. Six neonates were treated with this technique because of worsening pulmonary interstitial emphysema during extracorporeal circulation. Five of them survived. Another indication for extracorporeal membrane oxygenation in our pediatric population has been left ventricular or biventricular failure after cardiopulmonary bypass. Four of our seven patients treated for this indication are long-term survivors. At present, because of the impossibility of using other forms of left ventricular assist devices in the pediatric population, it seems that extracorporeal membrane oxygenation is the most effective treatment for left ventricular failure after cardiopulmonary bypass. From our experience, even in the absence of long-term follow-up of patients supported with extracorporeal membrane oxygenation, it appears that the benefits of this therapeutic modality far exceed the risks in the high-risk population for which it is being used.
Trento
A
A
Department of Surgery, University of Pittsburgh School of Medicine, Pa.
Thompson
A
A
Siewers
R D
RD
Orr
R A
RA
Kochanek
P
P
Fuhrman
B
B
Frattallone
J
J
Beerman
L B
LB
Fischer
D R
DR
Griffith
B P
BP
D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D002675:Child, Preschool; D015199:Extracorporeal Membrane Oxygenation / Q000639:trends*; D006333:Heart Failure / Q000209:etiology / Q000628:therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011182:Postoperative Care; D011183:Postoperative Complications / Q000628:therapy*; D011656:Pulmonary Emphysema / Q000628:therapy*; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy*; D012307:Risk Factors